CELL METAB:红葡萄表皮一物质可延缓衰老症状

2012-12-25 CELL METAB 中国新闻网

港大医学院最新研究发现,一种存在于红葡萄表皮的物质“白藜芦醇”,可以结合衰老中变异的人体蛋白质LAMINA,活化长寿基因SIRT1,显著延缓衰老症状;更成功透过实验证实,早老症老鼠的寿命因而延长三成,研究人员最终希望十年内可推出有效的抗衰老药物,以延长人类寿命及预防退化性疾病如骨质疏松症。   港大医学院生物化学系副教授周中军博士领导的研究,成功揭开人类衰老和抗衰老机制。研究人员透过



港大医学院最新研究发现,一种存在于红葡萄表皮的物质“白藜芦醇”,可以结合衰老中变异的人体蛋白质LAMINA,活化长寿基因SIRT1,显著延缓衰老症状;更成功透过实验证实,早老症老鼠的寿命因而延长三成,研究人员最终希望十年内可推出有效的抗衰老药物,以延长人类寿命及预防退化性疾病如骨质疏松症。
 
港大医学院生物化学系副教授周中军博士领导的研究,成功揭开人类衰老和抗衰老机制。研究人员透过老鼠实验得知,早老症患者因为身体蛋白质LaminA变异,令他们身体出现大量早老素,长寿基因SIRT1活性因而下降,导致干细胞数目和活性下降,身体机能随之逐渐衰老。
 
而一般人类衰老过程中,亦因为年龄而增加早老素,其后的衰老过程就与早老症一样。
 
在抗衰老方面,研究人员发现一种在红葡萄表皮和红酒的物质“白藜芦醇”,有效抗衰老。“白藜芦醇”可以结合人体内的LaminA,令LaminA具备能力刺激活性下降中SIRT1再次复活,增加干细胞数量,从而介入和延缓衰老过程。此项突破性研究刚发表于最新一期国际权威学术期刊《细胞代谢》(Cell Metabolism)中。
 
研究人员分别用两组各20只患上早老症的老鼠进行对照实验,一组老鼠每周喂饮约一至两毫克的“白藜芦醇”液体,另一组则没有。结果显示,有饮用“白藜芦醇”的老鼠存活5至7个月,比没有饮用的老鼠平均长寿2至3成,有使用“白藜芦醇”老鼠的骨质密度亦增加了7%,体重更上升3成。
 
周表示,现时已经在健康老鼠上进行同样实验,希望证实正常衰老情况下,“白藜芦醇”都可以延长寿命。他们也与美国早老症协会合作,于全球招募100名早老症病人,进行试药研究,现时已经招募50至60名病人。
 
港大医学院助理教授刘宝华表示,他们希望最终可以研发包括“白藜芦醇”或类似人体蛋白质LaminA的小分子药物,可用作活化SIRT1,从而增长人口寿命和减少衰老导致的疾病,但由于“白藜芦醇”已知会抑制一般细胞生长,制成药物仍面对相当难度,周中军仍希望可于10年内研发出新药。
白藜芦醇相关的拓展阅读:



Resveratrol Rescues SIRT1-Dependent Adult Stem Cell Decline and Alleviates Progeroid Features in Laminopathy-Based Progeria

Highlights
    Lamin A binds to and activates SIRT1 deacetylase
    Resveratrol enhances SIRT1 activity by increasing its interaction with lamin A
    Resveratrol, via SIRT1, rescues ASC decline in laminopathy-based premature aging mice
    Resveratrol alleviates progeroid features and extends life span in progeria mice

Summary

Abnormal splicing of LMNA gene or aberrant processing of prelamin A results in progeroid syndrome. Here we show that lamin A interacts with and activates SIRT1. SIRT1 exhibits reduced association with nuclear matrix (NM) and decreased deacetylase activity in the presence of progerin or prelamin A, leading to rapid depletion of adult stem cells (ASCs) in Zmpste24/mice. Resveratrol enhances the binding between SIRT1 and A-type lamins to increases its deacetylase activity. Resveratrol treatment rescues ASC decline, slows down body weight loss, improves trabecular bone structure and mineral density, and significantly extends the life span in Zmpste24/mice. Our data demonstrate lamin A as an activator of SIRT1 and provide a mechanistic explanation for the activation of SIRT1 by resveratrol. The link between conserved SIRT1 longevity pathway and progeria suggests a stem cell-based and SIRT1 pathway-dependent therapeutic strategy for progeria.

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958844, encodeId=6b08195884408, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 31 13:30:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895651, encodeId=fd38189565182, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 11:30:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868610, encodeId=43841868610e4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 07 02:30:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932362, encodeId=dbd2193236237, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Fri Aug 16 16:30:00 CST 2013, time=2013-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887335, encodeId=d897188e3351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 01 14:30:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
    2013-07-31 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958844, encodeId=6b08195884408, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 31 13:30:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895651, encodeId=fd38189565182, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 11:30:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868610, encodeId=43841868610e4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 07 02:30:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932362, encodeId=dbd2193236237, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Fri Aug 16 16:30:00 CST 2013, time=2013-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887335, encodeId=d897188e3351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 01 14:30:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
    2013-01-15 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958844, encodeId=6b08195884408, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 31 13:30:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895651, encodeId=fd38189565182, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 11:30:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868610, encodeId=43841868610e4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 07 02:30:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932362, encodeId=dbd2193236237, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Fri Aug 16 16:30:00 CST 2013, time=2013-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887335, encodeId=d897188e3351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 01 14:30:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958844, encodeId=6b08195884408, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 31 13:30:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895651, encodeId=fd38189565182, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 11:30:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868610, encodeId=43841868610e4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 07 02:30:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932362, encodeId=dbd2193236237, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Fri Aug 16 16:30:00 CST 2013, time=2013-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887335, encodeId=d897188e3351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 01 14:30:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958844, encodeId=6b08195884408, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 31 13:30:00 CST 2013, time=2013-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895651, encodeId=fd38189565182, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Tue Jan 15 11:30:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868610, encodeId=43841868610e4, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Apr 07 02:30:00 CST 2013, time=2013-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932362, encodeId=dbd2193236237, content=<a href='/topic/show?id=d8de4951168' target=_blank style='color:#2F92EE;'>#延缓衰老#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49511, encryptionId=d8de4951168, topicName=延缓衰老)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7f52347, createdName=soongzhihua, createdTime=Fri Aug 16 16:30:00 CST 2013, time=2013-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887335, encodeId=d897188e3351a, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Tue Oct 01 14:30:00 CST 2013, time=2013-10-01, status=1, ipAttribution=)]
    2013-10-01 guojianrong

相关威廉亚洲官网

白藜芦醇抑制乳腺癌细胞增殖(附点评)

 MedSci评论:  这篇文章比较可惜发表在国内杂志。虽然有关白藜芦醇抗肿瘤的研究,国际上已经很多,就本文研究而言,基本没有创新性。无论是研究白藜芦醇的抗增殖作用,还是其可能机制与MAPK-ERK1/2有关,均是相对过时的内容。但是,本文只要当时在研究方向进行稍改变,可能就是一篇非常优秀的论文。 例如,虽然williamhill asia 知道白藜芦醇能够抑制肿瘤细胞增殖,但是它对不同的乳腺癌

DIABETES:红酒护心,胖人不适用

  多项实验发现,红葡萄酒中的抗氧化剂白藜芦醇,对改善胰岛素敏感度和心脏健康具有一定的功效。然而,《糖尿病》杂志刊登丹麦一项新研究发现,对肥胖男性而言,喝红酒对他们的血糖和心脏健康没有益处。   在丹麦奥尔胡斯大学附属医院科学家完成的这项新研究中,两组肥胖男性参试者连续4周分别每天服用1.5克白藜芦醇和安慰剂,结果发现,在胰岛素敏感度方面,两组无区别。在血压和血脂等心脏健康指标方面,两组参试者也

EBM:饮食对生长追赶期骨质的影响及白藜芦醇的干预作用

虽然多数有关生长追赶期的研究都把焦点放在和胰岛素抗性相关的疾病的高风险上,然而生长追赶对于骨质代谢的影响,特别是对于成人骨质代谢的影响,仍鲜少被详细探讨。饮食是一可被控制的因子,于复食之后,不同饮食型态对于骨质的影响是一个值得深入研究的主题。白藜芦醇已经被证实对于哺乳类动物在生理上有许多正面的效果,其中也包含了促进骨质生长。华中科技大学同济医学院陈璐璐及其研究团队在2012年3月的《Experim

Kidney:白藜芦醇可改善败血症诱导的急性肾损伤

近日,Kidney杂志在线发表了美国阿肯色大学研究人员的成果,研究发现败血症患者发生AKI后其死亡率几乎增加了一倍,由于治疗只是在发生AKI后才开始,所以其疗效往往欠佳。 活性氮的产生可导致肾脏微循环的衰竭,白藜芦醇属于多酚类血管扩张药物,同时可以清除盲肠处穿刺结扎(CLP)诱发败血症诱导急性肾损伤鼠模型中活性氮,给药后在CLP 5.5h时在活体显微镜检查下可以发现逆转皮质毛细血管灌注的下降

PNAS:抗氧化剂白藜芦醇等或成为改进的抗癌药物

3月19日,国际著名杂志PNAS在线刊登了国外研究人员的最新研究成果“High-throughput genotoxicity assay identifies antioxidants as inducers of DNA damage response and cell death,”,文章中,研究者指出抗氧化剂可能会变成改进的抗癌药物。 在这项研究报告中,研究者表示抗氧化剂化合物包括白